Implementation Process Article 5(3) Nitrosamine
contact points as outlined on the EMA and CMDh websites. If the N-nitrosamine(s) identified exceed(s) the AI limit based on the ICH M7 principles, an investigation report should be submitted as part of the step 2 response (see chapter 3.1. for further
Download Implementation Process Article 5(3) Nitrosamine
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Quality Management System - objectives
apic.cefic.orgOverall, there is a clear tendency of authorities towards Quality Management Systems (QMS), as already outlined in some new guidelines, e.g. in ICH Q7a, Section 2.11 “Each manufacturer should establish, document, and implement an effective system for …
H A N D B O O K - WHO
www.who.intiii FOREWORD In order to assist countries in conducting non-clinical research and drug development, TDR developed a Good Laboratory Practices (GLP) series in 2001, comprising a GLP Handbook as well as GLP Training manuals for trainers and trainees. The demand for this series was so substantial that it became one of the most frequent “hits”
MedDRA TERM SELECTION: POINTS TO CONSIDER
admin.new.meddra.orgThis MedDRA Term Selection: Points to Consider (MTS:PTC) document is an ICH-endorsed guide for MedDRA users. It is updated annually in step with the March release of MedDRA (starting with MedDRA Version 23.0) and is support documentation for MedDRA. It was developed and is maintained by a working group charged by the ICH Management Committee.
Overview ICH GCP E6(R2) Integrated Addendum
about.citiprogram.orgThe ICH convened an expert working group to create an addendum to the existing E6 guideline. The expert working group was consisted of ICH members from both industry and regulatory agencies, as well as observers, to address current research topics like quality by design, quality risk management, and focus on
ICH QUALITY IMPLEMENTATION WORKING GROUP …
database.ich.orgICH Q8/Q9/Q10 Implementation Section 1. INTRODUCTION The ICH Quality Implementation Working Group (Q-IWG) has prepared ‘Points to Consider’ covering topics relevant to the implementation of ICH Q8(R2), Q9 and Q10, which supplement the existing Questions & Answers and workshop training materials already produced by this group.